The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...

Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste. This is the reality of CRISPR, a ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Jennifer Doudna, a UC Berkeley biochemist who shared the 2020 Nobel Prize in Chemistry for the invention of CRISPR-Cas9 ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Four MIT faculty members are among 23 world-class researchers who have been awarded the nation’s highest honors for scientists and innovators, the White House this week. Angela […] ...